Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck CEO Robert Davis joins 'Mornings with Maria' to discuss the new $1 billion biologics manufacturing facility slated to ...

As President Donald Trump hits 100 days in his second term, the administration is touting the billions of investments ...

The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...